Clear Search

Guilherme Nader-Marta, MD

Dana-Farber Cancer Institute
Boston, Massachusetts

Titles and Affiliations

Goldfarb Advanced Fellow
Conquer Cancer – The ASCO Foundation

Research area

Improving treatments for aggressive metastatic triple-negative breast cancer.


Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that often occurs in younger Black women. Treatment options for this type of cancer when it spreads to other parts of the body (a process called metastasis) are limited. The standard treatment for metastatic TNBC (mTNBC) has traditionally been chemotherapies which are often associated with significant side effects. Although recent advances have allowed the incorporation of new therapies, they only work well for some patients and are usually only able to keep the disease under control for a limited time. For this reason, innovative and effective therapeutic alternatives are needed for this disease.

What’s next

Some mTNBC have high levels of a protein called Prostate Specific Membrane Antigen (PSMA), which has been successfully used as a target for treatment in patients with prostate cancer. The treatment, called Lutetium-PSMA, has prolonged patients’ survival in men with prostate cancer compared to standard treatments. The aim of Dr. Nader-Marta’s Conquer Cancer research, supported by BCRF, is to evaluate the efficacy of Lutetium-PSMA in patients with mTNBC who have progressed on other treatments.


Guilherme Nader-Marta, MD received his medical degree from the University of Sao Paulo in Brazil and completed his oncology residency at the same institution. In 2021, he joined Jules Bordet Institute in Belgium as a clinical research fellow, where he is dedicated to breast cancer research. He is currently a PhD candidate at the Free University of Brussels (ULB) with a research focus on biomarkers and breast cancer special histological types, particularly lobular breast cancer. The results of his research have been presented at international conferences, published in peer-reviewed journals, and in recognition for the high quality of his work, Dr Nader-Marta received a Conquer Cancer Merit Award in 2022.

BCRF Investigator Since


Areas of Focus